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Renal hemodynamics and renal kinins after angiotensin-converting
enzyme inhibition. The effect of the angiotensin-converting enzyme
(ACE) inhibitor captopril on the renal kallikrein-kinin system and renal
hemodynamics was studied in anesthetised dogs for 45 mm after
captopril administration. ACE inhibition was confirmed by increases in
blood angiotensin I (Al) and plasma renin activity and a 20-fold
decrease in sensitivity of the blood pressure and renal blood flow dose-
response curves to Al. Captopril (1.5 mg kg', iv.) led to an increase
in renal blood flow of 56 13 ml/min' (P <
.01) despite a fall in mean
arterial pressure of 17 5mm Hg (P <0.005). Glomerular filtration rate
did not change whereas the filtration fraction decreased (P < 0.005).
The hypotension and renal vasodilation were accompanied by an
increase in urinary kinin excretion (P < .025) but no acute change in
circulating kinins or urinary kallikrein excretion. Urine volume and
urinary sodium and potassium excretion increased. To determine the
contribution of the renin-angiotensin system to these hemodynamic
changes, we gave captopril to a further group of dogs during a
continuous infusion of the competitive angiotensin 11 (All) receptor
antagonist sar'ile5-A1I (2.5 ig/kg/min). Subsequent ACE inhibition was
still associated with an increase in renal blood flow of 35 17 ml/min
(P < 0.05), decrease with a mean arterial pressure by II 4 mm Hg (P
< 0.025). These results suggest that ACE inhibition increases levels of
intra-renal kinins and that decreased degradation of these tissue vasodi-
lator peptides may contribute significantly to the acute renal vasodila-
tion and hypotensive effect of captopril.
Hémodynamique rénale et kinines rénales après inhibition de l'enzyme
de conversion de l'angiotensine. L'effet du captopril, inhibiteur de
l'enzyme de conversion de l'angiotensine (ACE), sur le système
kallicréine-kinine et l'hemodynamique rénale a etC CtudiC, chez des
chiens anesthCsiés, pendant 45 mm après l'administration de l'inhibi-
teur. L'inhibition de lACE a etC confirmCe par les augmentations de
l'angiotensine I (Al) et de l'activitC refine plasmatique et par une
diminution de 20 fois des courbes dose-response de Ia sensibilitC de Ia
pression artCrielle et du debit sanguin renal alA!. Le captopril(l,5 mg
kg-' i.v.) a déterminé une augmentation du debit sanguin renal de 56
13 ml min' (P < 0,01) malgré une diminution de Ia pression artérielle
moyenne de 17 5 mm Hg (P < 0,005). Le debit de filtration
glomerulaire n'a pas change et La fraction de filtration a diminué (P <
0,005). L'hypotension et Ia vasodilatation rénale ont été accompagnées
d'une augmentation de l'excrCtion urinaire de kinine (P < 0,025)
observée sans changement des kinines circulantes ou de l'excrétion
urinaire de kallicrCine. Le debit urinaire et les debits d'excrétion de
sodium et de potassium ont augmente. Afin de determiner La contribu-
tion du système renine-angiotensine a ces modifications hemodyna-
miques du captopril a etC administré a un autre groupe de chiens au
cours d'une pet-fusion continue de l'antagoniste compétitifdu rCcepteur
de l'angiotensine II (All), Ia sar'i1e8-AII (2,5 g/kg/min). L'inhibition
de l'ACE a encore Cté associCe a une augmentation du debit sanguin
renal de 35 17 ml min (P < 0,05) alors que Ia pression artCrielle
moyenne a diminué de II 4 mm Hg (P < 0,025). Ces rCsultats
suggèrent que l'inhibition de I'ACE augmente les concentrations intra-
rénales de kinines et que Ia diminution de Ia degradation de ces peptides
tissulaires vaso-dilatateurs peut contribuer significativement a l'effet du
captopril de vasodilatation rCnale aigue et d'hypotension.
The ACE inhibitor captopril (SQ 14,225) inhibits the conver-
sion of angiotensin I (Al) to the pressor peptide angiotensin II
(All), and the degradation of the depressor peptide bradykinin
(BK) to inactive fragments [11. Circulating Al and renin activity
increase after captopril is administered and circulating All
levels decrease [2—5]. Although conflicting results have been
obtained for levels of circulating BK after ACE inhibition [3—91,
changes in tissue levels of the renin-angiotensin system and
kallikrein-kinin system have not been measured.
It is now known that the kidney possesses a kallikrein-kinin
system located in the distal tubular segments [10, 11]. Further-
more, urinary excretion of kallikrein and kinins probably reflect
this renal system because urinary and renal tissue kallikrein
have been shown to be identical [12, 13] and circulating kinins
filtered at the glomerulus are destroyed in the proximal tubule
[14, 151. It is therefore possible that captopril may act on this
local tissue kallikrein-kinin system.
Both All and BK influence renal blood flow, renal function,
and renal sodium reabsorption. The ACE inhibitors teprctide
(SQ2O,88l) and captopril have been reported to increase renal
blood flow in dog and man [4, 5, 16, 17] though whether this is
due to a decrease in All or an increase in BK is unknown.
This paper reports the acute effects of ACE inhibition by
captopril on the urinary excretion of kallikrein, kinins, electro-
lytes, and water in anesthetized dogs and the resultant changes
in blood pressure and renal hemodynamics. To determine
which of the changes were due to inhibition of the renin-
angiotensin system, we repeated the ACE inhibition, in the
presence of complete All blockade, by an angiotensin receptor
antagonist.
Methods
Mongrel dogs (21.6 1.4 kg of body wt) on standard diet
(sodium, about 110 mEq/day; potassium, 80 mEq!day') were
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anesthetised with sodium pentobarhitone (30 mg/kg, i.v.) and
artificially ventilated. The femoral artery was cannulated for
arterial blood pressure measurement, and the femoral and
jugular veins were cannulated for infusions of saline, 3H-inulin,
and drugs. A saline load of 1 liter was administered over 90 mm
starting with surgery and continuing at I ml/min for the rest of
the experiment. Heart rate was measured by a tachygraph from
the ECG signal and blood pressure by a Statham strain gauge
transducer. The left kidney was exposed by an extraperitoneal
flank incision, and the left renal vein was cannulated by a
modification of the method of Herd and Barger [181 for the
collection of blood samples. The left ureter was cannulated for
timed collections of urine. GFR was calculated from 3H-inulin
clearance using 15-mm urine collection periods. Renal blood
flow was measured using a Biotronex electromagnetic flow
meter around the renal artery. Urine for measurement of
urinary kallikrein and kinins was collected into inhibitors of
kinin degradation (2.5 mmoles 1,10-phenanthroline, 2 mmoles
ethylene-diaminetetraacetic acid (EDTA), 3 mmoles sodium
azide).
Group 1 (N = 9 dogs). After two consecutive 15-mm control
periods, captopril 1.5 mg/kg in 10 ml of saline was given i.v.
Three further 15-mm experimental periods were studied. Blood
samples were withdrawn from the renal vein and femoral artery
at the beginning and end of each urine collection period. To
confirm ACE inhibition, we performed blood pressure and renal
blood flow dose-response curves to exogenous Al (50 to 5000
ng/kg1) before and 45 mm after capiopril,
Group 2 (N = 6 dogs). This group was studied with the same
protocol as group 1 dogs but received saline instead of capto-
pril.
Group 3 (N = 6 dogs). After control observations, these dogs
were given a continuous infusion of 2.5 p.g/kg/min of sar'ile8-
All, an All receptor antagonist. Thirty minutes later during the
continuous infusion of sarile8-A11, they were given captopril
(1.5 mg/kg) and studied in the same manner used for group 1.
Angiotensin blockade by the receptor antagonist was confirmed
by comparing the blood pressure and renal blood flow dose-
response to exogenous All (5 to 1000 ng/kg ) before and 100
mm after the sar'ile8-AII infusion was started.
Hormone assays. Blood BK and Al were measured by
radioimmunoassay from an ethanolic extract of blood following
the procedure of Mashford and Roberts [19] as previously
described [21. A 5-mi blood sample was collected into 20 ml of
ethanol, centrifuged, and the precipitate re-extracted with 20 ml
of 75% aqueous ethanol. The supernatants were combined and
divided into two equal parts, one of which was blown down,
ether washed, and then blown to dryness. This extract was
reconstituted in 0.1 M phosphate-saline-casein buffer (pH, 7.4)
containing EDTA and neomycin, and assayed for A!. The
remaining part of the ethanolic extract was loaded onto a 0.5-
cm-x-7.5-cm CM-Sephadex C25 column equilibrated in 0.075 M
ammonium acetate (pH, 5.0). The column was washed with this
buffer, and the BK was eluted with 1.0 M ammonium acetate
(pH, 7.0). The samples were lyophilized and reconstituted in 0.1
M Tris hydrochloric acid (pH, 7.4) containing EDTA and
phenanthroline, and assayed for BK. Recovery of added BK
was 84.2 3.2% and was determined for each experiment.
Plasma renin activity was measured by the method of John-
ston et a! [20].
Table 1. Blood pressure and renal hemodynamic measurements in 9
dogs given captopril (1.5 mg/kg I) and in 6 dogs given saline°
Control
Group 1: Captopril
Mean arterial pressure, 126 5
mm Hg
Heart rate, beats mm
Renal blood flow,
,ni/min
Renal vascular resistance,
mm Hg/mi mm
GFR, mlImin
Filtration fraction
Mean arterial pressure,
mm Hg
Heart rate, beats mm
Renal blood flow,
mi/mi,,
Renal vascular resistance,
mm Hg/mi mnin
GFR, mi/mm
Filtration fraction
a The control and experimental values are the average of two IS
minute periods. Values are the means SEM. Statistical significance for
changes determined by paired Student's t test.
Urinary kallikrein was measured with an enzymatic assay.
The BK generated from incubation of urine with dog kallikrein
substrate was determined by radioimmunoassay [21]. A 5-pJ
urine sample was diluted to 150 p.1 with 0.1 M glycine buffer
(pH, 9.0) and incubated with 100 p.1 of purified dog kallikrein
substrate for 5 mm at 370 C. The reaction was stopped with 500
p.! of ethanol, and the supernatant was assayed for BK. The
urine was radioimmunoassayed directly for kinins [22]. Lysyl-
BK and methionyl-lysyl-BK crossreact 100% and 90%, respec-
tively, in the assay, and urinary kinins are expressed as total
kinins excreted for each urine collection period.
Urinary electroLytes. Sodium and potassium were measured
using a flame photometer.
Statistics. The results are presented as the mean SEM. The
statistical significance of the changes were tested using the
paired or unpaired Student's I test or analysis of covariance
[23].
Results
Converting enzyme inhibition. Following captopril adminis-
tration, there was a significant rise in blood Al levels from 14.3
2.9 to 91.3 35.6 pg/mt (P < 0.05) together with a rise in
plasma renin activity from 0.86 0.26 to 4.74 1.81 ng All
m1'/hr (P < 0.05). The blood pressure and renal blood flow
dose-response curves to exogenous Al following captopril were
shifted 20-fold to the right.
Blood pressure andi'enal hetnodynamic changes after capto-
pril. The changes in mean arterial pressure, heart rate, renal
blood flow, renal vascular resistance, GFR, and filtration
fraction in the dogs given captopril (group I) or saline (group 2)
for the control periods and for the experimental periods 15 mm
after captopril are shown in Table I. No significant change
occurred in any of these parameters in group 2 dogs given
Experimental P
109 6 <0.01
137 6 <0.005
247 46 <0.01
119 7
192
0.77 0.17 0.49 0.11 <0.01
43.0 10.7 43.3 12.8 NS
0.36 0.05 0.30 0.05 <0.005
Group 2: Saline
123 5 128 4 NS
105 9 105 NS
199 201 NS
0.83 0.17 0.84 0.16 NS
44,4 6.3 44.7 7.7 NS
0.34 0.01 0.33 0.02 NS
vehicle alone. The changes in the captopril-treated dogs for all
the collection periods is illustrated in Figure I. Captopril in
these sodium-replete anesthetized dogs caused a sustained fall
in arterial blood pressure of 17 5 mm Hg but a significant
increase in renal blood flow of 56 13 ml/min' and a fall in
calculated renal vascular resistance of 36%. There was no
change in GFR, and the filtration fraction fell significantly.
Changes in circulating bradykinin after cap topril. The circu-
lating bradykinin levels before and after captopril are illustrated
in Figure 2 for groups I and 2. Neither arterial nor renal venous
levels changed with ACE inhibition, and thus the A/V ratio
remained close to one.
Changes in urinary volume, sodium, potassium, kinins, and
kallikrein. Captopril caused a significant diuresis and increase
in potassium excretion after 30 mm and a more gradual increase
in sodium excretion (Table 2). Group 2 dogs showed no
alteration in urinary volume, sodium or potassium excretion.
The urinary excretion of kinins increased significantly in the
captopril-treated dogs (Fig. 3). Only small changes occurred in
kallikrein excretion, and the changes did not significantly
parallel the kinin changes (P > 0.25, analysis of covariance).
The excretion of these substances did not change in the group 2
dogs given saline.
Effects of sar'ileangiotensin 11. Following All blockade
with 2.5 g/kg/min of sar'ile8-AII, the renal vasoconstrictor
dose-response curve to exogenous All was markedly shifted
1000-fold to the right, requiring more than 250 ng ATI/kg to
cause any decrease in renal blood flow or rise in blood pressure.
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Fig. 1. Changes in mean arterial pressure (MAP), renal blood flov
(RBF), GFR, and renal vascular resistance (RVR) for group I dogs
given captopril. C1 and C2 denote 15-mm control periods prior to
administration of captopril. E1, E2, and E3 denote 15-mm experimental
periods immediately following captopril. Values are the means SEM
Time, rn/n
Fig. 2. Circulating bradykinin levels before and after captopril for
groups I and 2. Values are the means SEM.
Infusion of sar'ile8-Al1 increased arterial blood pressure by 20
3 mm Hg, and renal blood flow fell by 48 12 ml/min',
reflecting the vascular agonist action of the competitive antago-
nist.
Captopril during sar'ile8-AII infusion. The effect of captopril
during the continuous infusion of 2.5 g/kg/min of sarile8-
All on mean arterial pressure, renal blood flow, GFR, and renal
vascular resistance are illustrated in Figure 4. Despite angioten-
sin blockade, renal blood flow again increased significantly by
35 17 ml/min (P < 0.05), and mean arterial pressure fell
significantly by 11 4 mm Hg (P < 0.025). Renal vascular
resistance decreased by 22%, and the GFR again remained
constant. Although these changes were less than that caused by
captopril in group 1 dogs, the changes in renal blood flow and
mean arterial pressure after ACE inhibition in groups I and 3
dogs were not significantly different.
Urinary kinin excretion increased in five out of the six
sar4le8-AIl-treated dogs, the mean excretion increasing from
32,3 8.5 to 41.1 10.7 ng/min* Captopril caused increases
of 8, 16, 18, 48, and 120% in these dogs, but the mean increase
was not statistically significant. In one dog in which kinin
excretion fell (—21%), renal blood flow did not change. Urinary
kallikrein excretion showed a transient increase from 10.5 1 .9
to 13.3 2.7 g BK/mt'/hr (P < 0.05) but returned to control
levels within 45 mm. There was, however, no significant
diuresis, natriuresis, or kaliuresis after captopril in the presence
of Al! blockade.
Discussion
ACE inhibition with captopril caused an increase in urinary
excretion of kinins. This could reflect changes in filtered kinins
or changes in intrarenal generation. Although no renal extrac-
tion or release of BK after captropril could be demonstraled in
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Table 2. Changes in urine parameters in 9 dogs of group I given captoprila
Captopril
Exp. 1 Exp. 2 Exp. 3
C1 C2 E E2 E3
Fig. 3. Urinary excretion of kinins and kallikrein before (C and C2) and
after (E1, E2, and E7) captoprilfhr groups 1 and 2.
this study, BK has been shown to be filtered by the kidney [16].
Ward et al [14] reported high concentrations of kininases,
including converting enzyme or kininase 11, in the brush border
of the proximal tubule, suggesting this is a major site of peptide
inactivation for extrarenal kinins. Carone et a! [24] found that
when 3H-BK was perfused into the proximal tubule only BK
metabolites were excreted in the urine, whereas when perfused
into the distal tubule 98% was recovered in urine. Captopril
may act to inhibit the kininase II in the proximal tubule and thus
increase urinary kinin excretion, but Nasjletti, Colina-Chourio,
and McGiff [16] could not demonstrate increased urinary kinin
excretion after BK infusion, even after ACE inhibition with
SQ20881. Alternatively, kinins generated intrarenally from re-
nal kallikrein, which has been localized in the distal tubular
cells [10, 111, may be protected from degradation by ACE
inhibition, and increased excretion in the urine may reflect
these increased cellular levels of kinins. Ørstavik, Gautvik, and
Nustad [25] have demonstrated that kallikrein is capable of
being transported across an epithelial barrier, and kallikrein has
been found in renal lymph [26], supporting the possibility of
intrarenal transport. Kinins may also pass from these cells into
C1 C2 E1 E2 E3
Fig. 4. Changes in mean arterial pressure (MAP), renal blood flow
(RBF), GFR, arid renal vascular resistance (RVR) fr group 3 dogs
given cuplopril during infusion of sar'i/e8 -All, 2 to5 p.g/kg/,nin. C and
C2 denote 15-mm control periods prior to administration of captopril.
E1, E2, and E3 denote IS-mm experimental periods immediately follow-
ing captopril.
the renal interstitium and vasculature and thereby influence
renal hemodynamics. Olsen and Arrigoni-Martelli [27] also
found urinary kinin excretion increased after captopril adminis-
tration in conscious dogs.
Reported changes in levels of circulating BK after ACE
inhibition have varied. Williams and Hollenberg [4] and Swartz
et al [6] found small transient increases in plasma BK levels in
sodium-deplete hypertensive patients infused with the ACE
inhibitor SQ20881 but no significant changes in normotensive
subjects. McCaa, Hall, and McCaa [5] found increased levels of
blood kinins after a few days of treatment with SQ 14225 in
sodium-deficient dogs, whereas Huithen and Hokfelt [7] report-
ed transiently decreased BK levels in hypertensive patients.
The failure to detect any change in blood BK levels after
captopril administration in this study is in agreement with the
results of Hollenberg et a! [8], Matthews and Johnston [9] and
Miller and Johnston [3], who all reported no significant change
in circulating BK after ACE inhibition in hypertensive and
normal man. The factors influencing circulating BK have not
been defined, however, and the physiologic significance of
blood BK is not known. Furthermore, ACE (kininase II) is not
Control
Urine volume, mlImin 0.70 0.10 1.04 0.14 1.13 0.l2b
Sodium excretion, p.Eq/min' 161 21 217 47 237 49
Potassium excretion, p.Eq/min' 25 3 29 6 31 5b
Each urine collection period was IS mm and the control value is the average of the 2 control periods.
p <0.05.
1.08 0.18
236
6
Values are the means SEM.
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the only degradative pathway for BK, and compensatory in-
creases in other kininases may occur after ACE inhibition.
Captopril also caused a marked increase in renal blood flow
despite a fall in mean arterial pressure. This renal vasodilation
could have been caused by either the decreased levels of the
vasoconstrictor All or increased levels of the vasodilator BK,
both a consequence of ACE inhibition. Thus, to eliminate the
effect of decreasing levels of All after captopril, dogs were
pretreated with the competitive All receptor antagonist sar'ile8-
All. But, captopril still caused hypotension and renal vasodila-
tion although the changes were slightly less than they were in
untreated dogs. This suggests that factors other than a decrease
in the activity of the renin-angiotensin system contributed to
these changes. Increased levels of intrarenal kinins may have
mediated the changes, and the demonstration of increased
urinary kinins after captopril independent of urinary kallikrein
changes supports this idea. Both BK and lysine-BK have been
previously shown to be potent renal vasodilators [16, 281.
Swartz et al [61 reported that infusions of All after ACE
inhibition restored mean arterial pressure to control levels but
that the plasma All levels achieved were higher after 30 miii
than control levels, suggesting that some other factor such as
BK may also be responsible for the hypotensive response to
ACE inhibition. McCaa [29] in long-term studies found, howev•-
er. that infusions of All at 5 ng/kg'/min restored mean arterial
pressure to almost normal levels after 3 days. Thurston and
Swales [301, Jandhyala, Washington, and Lokhandwala[3l] and
Vollmer et al [321 have all found that pretreatment with the Alit
competitive antagonist saralasin did not prevent a fall in blood
pressure after captopril, but they did not measure renal hemo
dynamics or kinin levels.
Wong and Zimmerman L331 have also studied the effect of
captopril after All blockade with saralasin. They used nonhy.
potensive hemorrhage as a prior stimulus to the renin-angioten-
sin system in anesthetized dogs and, in this renin-activated
state, hemorrhage following saralasin was associated with a
marked increase in renal blood flow, which captopril did not
further increase, It is noteworthy, however, that in three of the
eight dogs studied there was a 10 to 30% further increase in
renal blood flow after captopril. In the other five dogs, the renal
blood flow was not changed or decreased, and so the overall
change was not statistically significant. This result may reflect
differences in the response to captopril dependent on varying
levels of activation of the renin-angiotensin system. The au-
thors suggested that kinin potentiation may be responsible for
the renal blood flow increases after captopril that were ob-
served in some dogs. The diminished response to captopril in
the sar'ile8-AII-treated dogs in our study may reflect the
participation of the renin-angiotensin system, though the partial
agonist properties of the antagonist do not allow one to draw
this conclusion.
The results reported here suggest that bradykinin may play a
significant role in the renal hemodynamic changes produced by
acute ACE inhibition. The use of inhibitors of the kallikrein-
kinin system during administration of captopril would further
elucidate the role of the renal kallikrein-kinin system. But, the
kallikrein inhibitors aprotinin and soy-bean trypsin inhibitor do
not inhibit dog renal or urinary kallikrein in vitro (Moriwaki et
al [34] and Clappison et al. unpublished observation) and a
bradykinin receptor antagonist is not yet available.
This acute study over 45 mm suggests that the short-term
effects of ACE inhibition with captopril, as well as involving the
renin-angiotensin system, are mediated in part by the kallikrein-
kinin system.
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